Relevant biomarkers of kidney allograft rejection

Loga, Luminița; Dican, Lucia; Matei, Horea; Mărunţelu, Ion; Constantinescu, Ileana

doi:10.25122/jml-2022-0181

Cited by 4 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are various aspects related to renal involvement in autoimmunity [20,21]. HLA genes play a critical role in the ability of the immune system to recognize and respond to foreign substances, such as viruses and bacteria [22,23]. In the context of ESRD, dysregulation of the immune system, including aberrant expressions of HLA antigens, has been implicated in the development of kidney damage and inflammation.…”

Section: Discussionmentioning

confidence: 99%

Association between Human Leukocyte Antigen and End-Stage Renal Disease in Patients from Transylvania, Romania

Iancu Loga,

Dican,

Chiorean

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

End-stage renal disease (ESRD) is the final stage of chronic kidney disease. This study explored the association between human leukocyte antigen (HLA) and ESRD. The interaction between genetic and environmental factors may also play a role in the development of ESRD. The study included 2392 ESRD patients who were awaiting renal transplantation. Blood samples were genotyped by SSOP and SSP-PCR methods. Multivariate logistic regression analysis showed that HLA-A*11 (p = 0.027), HLA-A*34 (p = 0.017), HLA-A*69 (p = 0.012), HLA-B*41 (p < 0.001), HLA-B*50 (p = 0.004), HLA-DRB1*10 (p = 0.027), and HLA-DRB1*14 (p = 0.004) were positively associated with ESRD (OR > 1); HLA-DRB1*07 (p < 0.001), HLA-DRB1*08 (p = 0.005), and HLA-DRB1*13 (p < 0.001) were protective against ESRD (OR < 1); and the three-locus haplotype HLA-A*02–B*41–DRB1*03, containing one susceptible allele, was strongly associated with ESRD (p < 0.001, OR = 3.15). In conclusion, this retrospective analysis of HLA typing in patients with ESRD of various etiologies suggests that molecular data on the HLA polymorphism should be collected in order to identify high-risk ESRD patients and to improve graft survival after kidney transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between Human Leukocyte Antigen and End-Stage Renal Disease in Patients from Transylvania, Romania

Iancu Loga,

Dican,

Chiorean

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

Diagnostic significance of TGF-β1 in kidney recipients with graft dysfunction

Shevchenko,

Sharapchenko,

Velikiy

et al. 2023

RJTAO

View full text Add to dashboard Cite

Development of minimally invasive diagnosis techniques for complications in recipients, based on analysis of the levels of molecular and genetic biomarkers, is an urgent task facing modern transplantology. Transforming growth factor beta 1 (TGF-β1), which has multiple effects in the body, among the potential indicators of complications.Objective: to assess the diagnostic significance of serum TGF-β1 in kidney recipients with graft dysfunction.Materials and methods. The study included 129 kidney recipients aged 17 to 68 years and 35 healthy subjects. Serum TGF-β1 levels in the recipients were determined by immunoenzyme technique.Results. Kidney recipients included 95 patients with laboratory and clinical signs of graft dysfunction, who underwent biopsy of the transplanted kidney, followed by morphological examination, and 34 recipients with normal graft function. Serum TGF-β1 levels in the kidney recipients were significantly higher than in their healthy counterparts (p = 0.00001); it did not correlate with most blood test parameters; with the glomerular filtration rate (GFR). Kidney recipients with graft dysfunction had significantly higher TGF-β1 levels than other recipients (p = 0.018). In recipients with graft dysfunction, morphological study revealed the following: acute tubular necrosis (ATN, n = 11), acute T-cell mediated rejection (ACR, n = 26), acute antibody-mediated rejection (AMR, n = 35), non-immune-mediated nephrosclerosis with signs of calcineurin inhibitor nephrotoxicity (CNI nephrotoxicity, n = 13), and recurrent glomerulonephritis (chronic graft rejection, n = 10). Recipients with immune-mediated graft injury (ACR, AMR and chronic rejection) had higher serum TGF-β1 levels than recipients with graft dysfunction resulting from other causes, p < 0.0001. Kidney recipients with serum TGF-β1 levels above the threshold value of 94.3 ng/mL had a higher risk of immune-mediated graft dysfunction than other kidney recipients (RR = 2.2 ± 0.22 [95% CI 1.46–3.46]) with 77.5% test sensitivity and 60.3% specificity.Conclusion. The calculated threshold serum TGF-β1 level in kidney recipients can be considered as an auxiliary indicator of graft dysfunction resulting from acute or chronic rejection.

show abstract

Galectin-3 in recipients with kidney graft dysfunction: analysis of predictive significance

Velikiy,

Sharapchenko,

Gichkun

et al. 2024

RJTAO

View full text Add to dashboard Cite

One of the most pressing issues in contemporary transplantology is the ongoing search for less invasive methods that would identify potential complications that recipients of solid organ transplants may encounter. Profibrogenic factor galectin-3 (Gal-3) is a potential marker of such complications. It is presumed that it may be involved in regulatory processes in both physiological and pathological conditions; Gal-3 is of particular importance in diseases associated with chronic inflammation and fibrosis.Objective: to assess the predictive significance of Gal-3, determined in the recipients’ serum, in the pathology of a transplanted kidney.Materials and methods. The study included 138 kidney recipients aged from 5 to 68 years and a group of healthy individuals (n = 11). Recipients’ serum Gal-3 levels were measured by immunoenzymatic method.Results. Among the kidney recipients, 91 patients had kidney graft dysfunction according to laboratory and clinical data, which served as an indication to perform a graft biopsy with morphologic examination of the samples. In kidney recipients, Gal-3 levels were significantly different and higher than in healthy individuals, p = 0.017; it did not correlate with most blood test parameters, but there was an inverse correlation with graft glomerular filtration rate (GFR) (r = –0.174; p = 0.043). Recipients’ Gal-3 levels were independent of their tacrolimus blood levels. Kidney recipients with graft dysfunction had considerably higher Gal-3 levels (p = 0.0003) compared to those without. Comparative analysis significantly showed higher Gal-3 concentrations in recipients with acute cellular rejection (ACR, p = 0.005), antibody-mediated rejection (AMR, p = 0.016) and сalcineurin inhibitor (CNI) nephrotoxicity (p = 0.006) compared to recipients without dysfunction. Recipients with signs of CNI nephrotoxicity tended to have higher Gal-3 levels when compared to recipients with graft dysfunction of other etiology (p = 0.08). Kidney recipients with Gal-3 levels above the calculated threshold value of 7.63 ng/mL had a 2.89-fold higher risk of developing chronic graft dysfunction and/or requiring hemodialysis compared with the rest of the kidney recipients (RR = 2.89 ± 0.46 [95% CI 1.17–7.11]), with 76.2% sensitivity and 56.1% specificity of the test.Conclusion. The threshold serum Gal-3 level in kidney recipients can be considered a predictor of an unfavorable graft outcome (chronic graft dysfunction and/or a need for renal replacement therapy).

show abstract

Relevant biomarkers of kidney allograft rejection

Cited by 4 publications

References 38 publications

Association between Human Leukocyte Antigen and End-Stage Renal Disease in Patients from Transylvania, Romania

Association between Human Leukocyte Antigen and End-Stage Renal Disease in Patients from Transylvania, Romania

Diagnostic significance of TGF-β1 in kidney recipients with graft dysfunction

Galectin-3 in recipients with kidney graft dysfunction: analysis of predictive significance

Contact Info

Product

Resources

About